Pfizer will run out of penicillin doses that treat common infections like syphilis, strep throat, and others

Per Bloomberg

Pfizer has recently released a letter detailing how the pharmaceutical giant is expected to run out of "several doses of penicillin." This comes as the company says that the shortage is due to supply interruptions.

The type of penicillin that Pfizer will run out of is used to treat some infections like syphilis and strep throat. Specifically, the company expects Bicillin L-A, a syphilis drug in children's doses, is expected to run out by the end of June.

The larger dose of the Bicillin L-A is now going to be the focus of the company. This type of penicillin is reportedly for pregnant people with syphilis.  

The Bicillin C-R, which treats other bacterial infections, is expected by the company to run out on September 30.

Pfizer's letter detailed the company's take on the shortage and how it was due to supply interruptions.

“The supply interruption is the result of a complex combination of factors including significant increases in demand, due to an increase in syphilis infection rates as well as competitive shortages,”

In January, Pfizer reportedly had Twitter censor users tweeting at them regarding inquiries about generic low-cost vaccines. This information came from Lee Fang of Twitter Files.

It was revealed that BioNTech emailed Twitter directly in order to ask its moderators to censor the tweets directed at them, asking whether the company would share its intellectual property.

It was revealed that Scott Gottlier emailed a top lobbyist in Twitter's Washington Office regarding Covid vaccine comments. Scott Gottlieb was a Pfizer board person who spotted a tweet by Dr. Brett Giroir explaining the difference between vaccine protection and natural immunity, saying the latter was more effective.

Dr. Gottlieb reportedly messaged Twitter to share concerns regarding the post. Dr. Brett Giroir was a physician.

See flow at unusualwhales.com/flow.

Other News:

Resources:

Bloomberg